Investor Relations

VBL Therapeutics (Nasdaq: VBLT) is developing targeted therapies for people living with immune-inflammatory diseases.

Press Releases

September 1, 2022
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Read More
August 15, 2022
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
Read More

Events & Presentations

More events are coming soon.

Corporate Presentation

More information is coming soon.
September 10, 2022 8:20 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart